The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis
Histone deacetylase inhibitor (HDACi) is a drug mainly used to treat hematological tumors and breast cancer, but its inhibitory effect on breast cancer falls short of expectations. Grape seed proanthocyanidin extract (GSPE) with abundant proanthocyanidins (PAs) has been explored for its inhibition o...
Main Authors: | Tsz Ki Wang, Shaoting Xu, Yuanjian Fan, Jing Wu, Zilin Wang, Yue Chen, Yunjian Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/13/10476 |
Similar Items
-
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
by: Robert Jenke, et al.
Published: (2021-02-01) -
The Role of HDACs as Leukemia Therapy Targets using HDI
by: Ahmad Ahmadzadeh, et al.
Published: (2016-02-01) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01) -
HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
by: Jie Wang, et al.
Published: (2022-12-01) -
The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
by: Saikat Dewanjee, et al.
Published: (2021-05-01)